NASDAQ:PBYI

Puma Biotechnology (PBYI) Stock Forecast, Price & News

$2.63

-0.02 (-0.75%)

(As of 09/29/2023 ET)

Compare

Today's Range: $2.60
▼
$2.74
50-Day Range: $2.63
▼
$4.09
52-Week Range: $2.08
▼
$5.16

Volume: 105,879 shs
Average Volume: 244,376 shs
Market Capitalization: $124.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Puma Biotechnology MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 204.2% Upside
$8.00 Price Target
Short Interest: Bearish
4.67% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.17
Based on 5 Articles This Week
Insider Trading: Selling Shares
$272,466 Sold Last Quarter
Proj. Earnings Growth: -29.27%
From $0.41 to $0.29 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

785th out of 973 stocks

Pharmaceutical Preparations Industry

375th out of 450 stocks

3.5

Analyst's Opinion

Consensus Rating
Puma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Puma Biotechnology has a forecasted upside of 204.2% from its current price of $2.63.
Amount of Analyst Coverage
Puma Biotechnology has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
4.67% of the float of Puma Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Puma Biotechnology has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Puma Biotechnology has recently increased by 3.59%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Puma Biotechnology does not currently pay a dividend.
Dividend Growth
Puma Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PBYI.

1.8

News and Social Media Coverage

News Sentiment
Puma Biotechnology has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Puma Biotechnology this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $272,466.00 in company stock.
Percentage Held by Insiders
22.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
55.97% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Puma Biotechnology are expected to decrease by -29.27% in the coming year, from $0.41 to $0.29 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Puma Biotechnology is -52.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Puma Biotechnology is -52.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Puma Biotechnology has a PEG Ratio of 1.07. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Puma Biotechnology has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

PBYI Price History

30 days | 90 days | 365 days | Advanced Chart

PBYI Stock News Headlines

September 23, 2023 | americanbankingnews.com

Puma Biotechnology, Inc. Expected to Earn Q4 2023 Earnings of $0.27 Per Share (NASDAQ:PBYI)

September 22, 2023 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Rating Reiterated by HC Wainwright

September 29, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 22, 2023 | americanbankingnews.com

Zacks Research Weighs in on Puma Biotechnology, Inc.'s FY2025 Earnings (NASDAQ:PBYI)

September 21, 2023 | marketwatch.com

Puma Biotechnology Gets Orphan Designation for Small Cell Lung Cancer Drug

September 21, 2023 | marketwatch.com

Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation

September 21, 2023 | finance.yahoo.com

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

September 19, 2023 | americanbankingnews.com

Critical Analysis: Hoth Therapeutics (NASDAQ:HOTH) versus Puma Biotechnology (NASDAQ:PBYI)

September 29, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

August 31, 2023 | finance.yahoo.com

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 4, 2023 | finance.yahoo.com

Q2 2023 Puma Biotechnology Inc Earnings Call

August 4, 2023 | finance.yahoo.com

Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform

August 4, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Puma Biotechnology (PBYI)

August 3, 2023 | msn.com

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

July 20, 2023 | finance.yahoo.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

July 7, 2023 | gurufocus.com

Insider Sell: Chief Commercial Officer Jeffrey Ludwig Sells 12,103 Shares of Puma Biotechnology Inc

June 4, 2023 | finance.yahoo.com

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

June 1, 2023 | msn.com

PBYI or TECH: Which Is the Better Value Stock Right Now?

May 28, 2023 | finance.yahoo.com

Should You Be Concerned About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE?

May 16, 2023 | msn.com

PBYI vs. TECH: Which Stock Is the Better Value Option?

May 6, 2023 | msn.com

HC Wainwright & Co. Reiterates Puma Biotechnology (PBYI) Buy Recommendation

May 5, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Regeneron (REGN) and Puma Biotechnology (PBYI)

May 5, 2023 | finance.yahoo.com

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

May 5, 2023 | finance.yahoo.com

Q1 2023 Puma Biotechnology Inc Earnings Call

May 4, 2023 | msn.com

Puma Biotechnology: Q1 Earnings Insights

May 4, 2023 | finance.yahoo.com

Puma Biotechnology Reports First Quarter Financial Results

April 17, 2023 | finance.yahoo.com

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

See More Headlines

Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Company Calendar

Last Earnings: 8/03/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PBYI
CUSIP: N/A
CIK: 1401667
Web: www.pumabiotechnology.com
Phone: (424) 248-6500
Fax: 424-248-6501
Employees: 192
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +204.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 6.41
P/E Growth: 1.07
Net Income: N/A
Net Margins: -1.09%
Pretax Margin: -0.76%
Return on Equity: -10.00%
Return on Assets: -1.22%

Debt

Debt-to-Equity Ratio: 2.88
Current Ratio: 1.97
Quick Ratio: 1.84

Sales & Book Value

Annual Sales: $228 million
Price / Sales: 0.55
Cash Flow: $0.19 per share
Price / Cash Flow: 13.71
Book Value: $0.47 per share
Price / Book: 5.60

Miscellaneous

Outstanding Shares: 47,510,000
Free Float: 36,725,000
Market Cap: $124.95 million
Optionable: Optionable
Beta: 1.06

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Alan H. Auerbach (Age 53)
Founder, Chairman, Pres, CEO & Sec.
Comp: $1.74M

Mr. Maximo F. Nougues (Age 54)
CFO & Principal Accounting Officer
Comp: $781.47k

Dr. Alvin F. Wong Pharm.d. (Age 70)
Chief Scientific Officer
Comp: $809.69k

Mr. Douglas Hunt B.Sc. (Age 58)
FRAPS, Sr. VP of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law
Comp: $632.65k

Mr. Jeffrey Jerome Ludwig (Age 57)
Chief Commercial Officer
Comp: $916.85k

Mr. Mariann Ohanesian
Sr. Director of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PBYI Stock - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings or view top-rated stocks.
What is Puma Biotechnology's stock price forecast for 2023?: 1 Wall Street analysts have issued 12-month price targets for Puma Biotechnology's stock. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 204.2% from the stock's current price.
View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts.
How have PBYI shares performed in 2023?: Puma Biotechnology's stock was trading at $4.23 on January 1st, 2023. Since then, PBYI shares have decreased by 37.8% and is now trading at $2.63.
View the best growth stocks for 2023 here.
When is Puma Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PBYI earnings forecast.
How were Puma Biotechnology's earnings last quarter?: Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The biopharmaceutical company had revenue of $54.60 million for the quarter, compared to analyst estimates of $51.37 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 10.00% and a negative net margin of 1.09%.
What guidance has Puma Biotechnology issued on next quarter's earnings?: Puma Biotechnology updated its third quarter 2023 earnings guidance on Friday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $54.00 million-$58.00 million, compared to the consensus revenue estimate of $60.49 million.

What other stocks do shareholders of Puma Biotechnology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and
What is Puma Biotechnology's stock symbol?: Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How do I buy shares of Puma Biotechnology?: Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Puma Biotechnology's stock price today?: One share of PBYI stock can currently be purchased for approximately $2.63.
How much money does Puma Biotechnology make?: Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $124.95 million and generates $228 million in revenue each year.
How many employees does Puma Biotechnology have?: The company employs 192 workers across the globe.
How can I contact Puma Biotechnology?: Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.

This page (NASDAQ:PBYI) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial